Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited of $575 million aggregate principal amount of its 0.000% convertible senior notes due 2025 (which includes $75 million principal amount of convertible senior notes from the full exercise of the initial purchasers’ over-allotment option).
NovoCure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associate Heita Miki. The equity derivatives team included partner Mark M. Mendez and associates Hanbing Zhang and Danielle Forni. Partner Mike Farber and associate Yixuan Long provided tax advice. Partner Frank J. Azzopardi and associate Yifu Chen provided intellectual property advice. All members of the Davis Polk team are based in the New York office.